Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor‐Positive Recipient‐Negative Mismatched Heart Transplant Recipients: An Observational Study
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70223 ↗At a glance
Beobachtungsstudie in Clinical Transplantation, 2025. Written by Alainee Miller and 7 co-authors. Institution: Department of Pharmacy, Memorial Hermann - Texas Medical Center, Houston, Texas, USA. Major MEDLINE topics: Heart Transplantation, Cytomegalovirus Infections, Antiviral Agents, Valganciclovir. 15 references.
Abstract (original language)
Background
Recommendations remain unclear between a shorter or extended CMV prophylaxis duration in donor seropositive/recipient seronegative (D+/R–) heart transplant recipients. The purpose of our study is to evaluate the effectiveness of a short (less than 145 days) versus extended (145 days or more) duration of CMV prophylaxis with ganciclovir (GCV)/valganciclovir (VGCV) for prevention of CMV viremia in this high‐risk patient population.
Methods
A retrospective cohort study was conducted of adult (age ≥ 18 years) CMV D+/R– heart transplantation recipients who received intravenous (IV) GCV or oral (PO) VGCV after transplant for CMV prophylaxis. CMV viremia/disease, time to CMV viremia/disease, hospitalizations, and mortality within the first year of transplant were assessed.
Results
A total of 55 D+/R– heart transplant recipients were included in this study, with 28 recipients receiving short duration prophylaxis and 27 recipients receiving extended duration. The median (IQR) duration of therapy for the short and extended duration groups was 76 (69–100) and 189 (168–278) days, respectively. There were similar rates of CMV viremia (35.7% vs. 48.1%; p = 0.35) and CMV disease (10.7% vs. 11.1%, p = 0.96) between the short and extended duration prophylaxis groups. The outcomes of time to CMV from transplant, CMV hospitalization, and mortality were also similar between groups.
Conclusion
In the present study, no difference was observed in the incidence of CMV viremia within 1 year between short versus extended duration of GCV/VGCV prophylaxis in CMV D+/R– heart transplant recipients. Prospective studies with a larger sample size may be needed to confirm this finding.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Memorial Hermann - Texas Medical Center, Houston, Texas, USA.
- Department of Advanced Cardiopulmonary Therapies and Transplantation, University of Texas Health Science Center at Houston, Center for Advanced Heart Failure, Houston, Texas, USA.
ORCID profiles: Phillip Weeks, Igor Gregoric
Cite
APA
Miller, A., Weeks, P., Drake, T., Sobhanian, M., Nathan, S., Patarroyo-Aponte, M., Gregoric, I., & Kar, B. (2025). Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor‐Positive Recipient‐Negative Mismatched Heart Transplant Recipients: An Observational Study. Clinical Transplantation. https://doi.org/10.1111/ctr.70223
Vancouver
Miller A, Weeks P, Drake T, Sobhanian M, Nathan S, Patarroyo-Aponte M, et al. Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor‐Positive Recipient‐Negative Mismatched Heart Transplant Recipients: An Observational Study. Clinical Transplantation. 2025. doi:10.1111/ctr.70223
BibTeX
@article{Miller2025,
author = {Miller, Alainee and Weeks, Phillip and Drake, Ty and Sobhanian, Minoosh and Nathan, Sriram and Patarroyo-Aponte, Maria and Gregoric, Igor and Kar, Biswajit},
title = {Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor‐Positive Recipient‐Negative Mismatched Heart Transplant Recipients: An Observational Study},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70223}
}
EUVIMED